{"id":"NCT02565914","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation","officialTitle":"A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-08","primaryCompletion":"2019-05","completion":"2022-12-05","firstPosted":"2015-10-01","resultsPosted":"2020-06-16","lastUpdate":"2023-09-28"},"enrollment":1131,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"TEZ/IVA","otherNames":["VX-661/VX-770","tezacaftor/ivacaftor"]},{"type":"DRUG","name":"IVA","otherNames":["VX-770","ivacaftor"]}],"arms":[{"label":"TEZ/IVA","type":"EXPERIMENTAL"}],"summary":"This is a Phase 3, multicenter, open-label, 3-part rollover study in subjects with CF who are homozygous or heterozygous for the F508del-CFTR mutation and who participated in studies VX13-661-103 (Study 103, NCT02070744), VX14-661-106 (Study 106, NCT02347657), VX14-661-107 (Study 107, NCT02516410), VX14-661-108 (Study 108, NCT02392234), VX14-661-109 (Study 109, NCT02412111), VX14-661-111 (Study 111, NCT02508207), VX15-661-112 (NCT02730208), and VX16-661-114 (NCT03150719). The study is designed to evaluate the safety and efficacy of long-term treatment of VX-661 in combination with ivacaftor.","primaryOutcome":{"measure":"Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)","timeFrame":"Day 1 up to Week 100","effectByArm":[{"arm":"Part A: TEZ/IVA","deltaMin":995,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":5},"locations":{"siteCount":154,"countries":["United States","Australia","Austria","Belgium","Canada","Denmark","France","Germany","Ireland","Israel","Italy","Netherlands","Spain","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":["33581080"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":351,"n":1042},"commonTop":["Infective pulmonary exacerbation of cystic fibrosis","Cough","Nasopharyngitis","Sputum increased","Haemoptysis"]}}